GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
Volume 68, Issue 5, Pages 557-567
Publisher
Wiley
Online
2014-02-06
DOI
10.1111/ijcp.12361
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AACE Comprehensive Diabetes Management Algorithm 2013
- (2015) Alan Garber et al. Endocrine Practice
- Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS)
- (2013) Eyal Leibovitz et al. Cardiovascular Diabetology
- Incretin Therapy and Islet Pathology: A Time for Caution
- (2013) S. E. Kahn DIABETES
- Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
- (2013) A. E. Butler et al. DIABETES
- Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
- (2013) J. Rosenstock et al. DIABETES CARE
- A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks
- (2013) M. A. Nauck DIABETES CARE
- Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
- (2013) Bo Ahrén et al. DIABETES CARE
- Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)
- (2013) M. Pinget et al. DIABETES OBESITY & METABOLISM
- Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis
- (2013) Y. G. Kim et al. DIABETOLOGIA
- Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control
- (2013) Helena Rodbard et al. Endocrine Practice
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular effects of the DPP-4 inhibitors
- (2012) Tessey Jose et al. Diabetes & Vascular Disease Research
- Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A randomized, open-label trial
- (2012) R. E. Pratley et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- Acute tubulointerstitial nephritis following treatment with exenatide
- (2012) H. Nandakoban et al. DIABETIC MEDICINE
- Liraglutide Achieves A1C Targets More Often Than Sitagliptin or Exenatide when Added to Metformin in Patients with Type 2 Diabetes and a Baseline A1C
- (2012) Allen King et al. Endocrine Practice
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- Liraglutide-Induced Acute Kidney Injury
- (2012) Yaman Kaakeh et al. PHARMACOTHERAPY
- Drug-Induced Generalized Skin Eruption in a Diabetes Mellitus Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor Plus Metformin
- (2012) Kaori Nakatani et al. Diabetes Therapy
- Cardiovascular Effects of Glucagonlike peptide–1 Agonists
- (2011) Michael H. Davidson AMERICAN JOURNAL OF CARDIOLOGY
- GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
- (2011) N. Mentis et al. DIABETES
- Weight-Related Quality of Life, Health Utility, Psychological Well-Being, and Satisfaction With Exenatide Once Weekly Compared With Sitagliptin or Pioglitazone After 26 Weeks of Treatment
- (2011) J. H. Best et al. DIABETES CARE
- Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study
- (2011) J. K. Berg et al. DIABETES OBESITY & METABOLISM
- Exenatide Once-Weekly Clinical Development: Safety and Efficacy Across a Range of Background Therapies
- (2011) Anthony Stonehouse et al. Diabetes Technology & Therapeutics
- Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
- (2011) Mary Beth DeYoung et al. Diabetes Technology & Therapeutics
- DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
- (2011) C. Wysham et al. DIABETIC MEDICINE
- One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
- (2011) R. Pratley et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
- (2010) K. J. Hare et al. DIABETES
- DPP-4 inhibitors: What may be the clinical differentiators?
- (2010) John Gerich DIABETES RESEARCH AND CLINICAL PRACTICE
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
- (2010) Richard E Pratley et al. LANCET
- Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers
- (2010) Alfonso López-Ruiz et al. PHARMACY WORLD & SCIENCE
- Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
- (2010) Ulrich Werner et al. REGULATORY PEPTIDES
- Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results
- (2009) Sten Madsbad BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
- (2009) J. A. DAVIDSON CLEVELAND CLINIC JOURNAL OF MEDICINE
- Exenatide-Associated Ischemic Renal Failure
- (2009) W. J. Weise et al. DIABETES CARE
- Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study
- (2009) R. A. Noel et al. DIABETES CARE
- Benefits of moderate weight loss in patients with type 2 diabetes
- (2009) Ken Fujioka DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Incretin-based therapies for type 2 diabetes mellitus
- (2009) Julie A. Lovshin et al. Nature Reviews Endocrinology
- Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
- (2008) Ralph A. DeFronzo et al. CURRENT MEDICAL RESEARCH AND OPINION
- Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes
- (2008) A. Nicolucci et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Influences of weight loss on long-term diabetes outcomes
- (2008) Lorna S. Aucott PROCEEDINGS OF THE NUTRITION SOCIETY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now